Vaccine offers approach to blocking infections

A novel vaccine developed at The Scripps Research Institute at La Jolla may offer a new way to block infections without sparking bacterial resistance--a process that gradually dilutes the effectiveness of antibiotics. Reporting in Chemistry and Biology, the team focused on blocking the communication link among bacteria--which is necessary to make them virulent. The team designed a molecule that spurs production of antibodies by the immune system.

"Bacteria basically sense they have enough of their buddies around to allow them to say, 'OK, we're in a favorable environment to start turning on certain genes,'" says team leader Professor Kim Janda, director of the Worm Institute for Research and Medicine at Scripps Research. But if you stop bacteria from communicating, they can't organize an assault on the body.

- read the release on the vaccine program

Suggested Articles

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

GigaGen joined a group of companies making plasma-based, polyclonal antibody treatments for COVID-19.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.